| Not Yet Recruiting | Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following NCT05554419 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger Than 60 Years Old NCT04269213 | Roswell Park Cancer Institute | Phase 2 |
| Withdrawn | Comparing ATG or Post-Transplant Cyclophosphamide to Calcineurin Inhibitor-Methotrexate as GVHD Prophylaxis Af NCT03602898 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the Treatment of Relapsed Refractory Pediatr NCT04915612 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Mye NCT04214249 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Mye NCT04284787 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) NCT04190550 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Synd NCT03953898 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or NCT03874052 | Jennifer Saultz | Phase 1 |
| Recruiting | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Ris NCT03670966 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Pevonedistat, Azacitidine, Fludarabine Phosphate, and Cytarabine in Treating Patients With Relapsed or Refract NCT03813147 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | Hu8F4 in Treating Patients With Advanced Hematologic Malignancies NCT02530034 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Cognitive Behavioral Therapy in Helping Patients With Acute Myeloid Leukemia or Lymphoma With Cancer-Related F NCT03747757 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients With Relapsed or NCT03672539 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndr NCT03630991 | M.D. Anderson Cancer Center | Phase 1 |
| Active Not Recruiting | Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Diso NCT03289910 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acu NCT03519984 | University of Southern California | Phase 1 |
| Active Not Recruiting | Pevonedistat, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia NCT03330821 | University of Southern California | Phase 1 / Phase 2 |
| Terminated | Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed NCT03404193 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, A NCT03128034 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic NCT03146871 | University of Southern California | Phase 2 |
| Terminated | Avelumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia NCT02953561 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Engineered Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies NCT02960646 | M.D. Anderson Cancer Center | Phase 1 |
| Completed | Vosaroxin and Infusional Cytarabine in Treating Patients With Untreated Acute Myeloid Leukemia NCT02658487 | Vanderbilt-Ingram Cancer Center | Phase 2 |
| Completed | Nivolumab in AML in Remission at High Risk for Relapse NCT02532231 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | 8-Chloroadenosine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT02509546 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Completed | CPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid Leukemia NCT02286726 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Lirilumab and Azacitidine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia NCT02399917 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Nivolumab and Azacitidine With or Without Ipilimumab in Treating Patients With Refractory/Relapsed or Newly Di NCT02397720 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Natural Killer Cells Before and After Donor Stem Cell Transplant in Treating Patients With Acute Myeloid Leuke NCT01904136 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Clofarabine and Melphalan Before Donor Stem Cell Transplant in Treating Patients With Myelodysplasia, Acute Le NCT01885689 | City of Hope Medical Center | Phase 2 |
| Terminated | Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant NCT02038153 | Albert Einstein College of Medicine | Phase 1 / Phase 2 |
| Completed | Donor Natural Killer Cells and Donor Stem Cell Transplant in Treating Patients With High Risk Myeloid Malignan NCT01823198 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia NCT01664897 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloi NCT01757639 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelog NCT01620216 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia NCT01420926 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia NCT01238211 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute My NCT01260714 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Veliparib and Temozolomide in Treating Patients With Acute Leukemia NCT01139970 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Lenalidomide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia NCT01132586 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Dono NCT00589316 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia NCT00392353 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonoc NCT00313586 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission NCT00093470 | National Cancer Institute (NCI) | Phase 3 |
| Completed | Fludarabine and Busulfan Followed by Allogeneic Stem Cell Transplant in Treating Older Patients With Acute Mye NCT00070135 | Alliance for Clinical Trials in Oncology | Phase 2 |